Skip to the page

Data / Form D filings / Entera Bio Ltd.

Entera Bio Ltd.: Form D filings

Entera Bio Ltd., a biotechnology company in Jerusalem, Israel, filed 4 Form D notices with the SEC between 2017 and 2026. The latest, on August 12, 2026, reports $275 million sold of a $275 million offering to 53 investors.

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

Company details from the filing

Address
Kiryat Hadassah - Minray Building Fifth Floor, Jerusalem, Israel, 91120
Phone
972-2-532-7151
Industry
Biotechnology
Entity type
Corporation
Incorporated in
Israel
Revenue range
Decline to Disclose
Exemptions claimed
Rule 506(b)
SEC identifier (CIK)
1638097

Form D filings

FiledTypeOfferingSoldRemainingInvestorsFirst saleFiling
Aug 12, 2026New notice$274,999,976$274,999,97653Jul 28, 2026sec.gov
Jan 2, 2024New notice$6,610,604$6,610,60452Dec 20, 2023sec.gov
Dec 26, 2019New notice$13,533,000$13,533,00052Dec 11, 2019sec.gov
Oct 19, 2017New notice$7,000,000$2,022,944$4,977,05630Oct 4, 2017sec.gov

Executive officers and directors named in the filing

NameRoleNote in the filing
Miranda ToledanoExecutive Officer, DirectorChief Executive Officer
Haya TaitelDirector
Yonatan MalcaDirector
Dana Yaacov-GarbeliExecutive OfficerChief Financial Officer
Geno J. GermanoDirectorChairman of the Board
Sean EllisDirector
Steven D. RubinDirector

Every Form D from the week of Aug 10, 2026 · All recent Biotechnology filings

Read from SEC EDGAR. Amount sold is what Entera Bio Ltd. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.